🔎 Trials Near Me

Utama › Limfoma Sel-B › Massachusetts

Kajian klinikal Limfoma Sel-B di Massachusetts

8 kajian untuk Limfoma Sel-B sedang mencari peserta di lokasi di Massachusetts.

Bandar di Massachusetts

Teks kajian rasmi (Bahasa Inggeris)

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  • Dana Farber Cancer Institute Longwood Medical Center, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06742996

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  • Research Site, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06564038

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04104776

DALY II USA/ MB-CART2019.1 for DLBCL

  • Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

  • Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Mac 2026 · NCT06026319

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

  • Harvard Medical School - Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1/2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 24 Ogo 2025 · NCT05607420

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.